DMD patients
Phase
VBP15 pharmacodynamics
Clinical Trials of VBP15
orphan drug VBP15
young ambulant DMD boys
Duchenne Muscular Dystrophy VISION-DMD
tolerability of ascending doses of VBP15
Innovative Steroid
better CS efficacy
delay disease progression
slow disease progression
clinical programme
clinical development
muscle strength
rare muscle
drug months
effects
efficacy data collection
long term safety
muscle cellular pathology
global acceptance
Innovative exploratory serum biomarkers
better treatment
standard of care
widespread acceptance
new therapy
affordable therapy
extension studies
leading networks TREAT-NMD
novel wide scale MRI techniques
trial delivery
ECRIN-ERIC
CINRG
FDA
results
government grants
international patient groups
Intervention
regulatory undertakings
cumulative exposure
membrane stabilization
quality of life
Europe
therapeutic window
unmet need
EMA advice
Test
ambulation
lifespan
incurable
registration
reliable primary endpoint
death
early adulthood
combination
Consortium
line
stratified therapies
IRDiRC goals
project
Time
Corticosteroids